spacer
home > pmps > winter 2003 > the countdown starts for implementing new child-resistant/senior-friendly blister packaging
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Countdown Starts for Implementing New Child-Resistant/Senior-Friendly Blister Packaging

In August 2003, the Medicines & Healthcare Products Regulatory Agency (MHRA) announced that the Government had accepted its recommendations for the introduction of greater safety measures on certain non-reclosable blister-packed drugs. These recommendations were put forward following the tragic death of a toddler after he accidentally overdosed on iron tablets contained in a standard blister pack.

Following this, on the 1st October 2003 a new legal standard for drugs packaging came into force. This new legislation marked the first step in moving the pharmaceutical industry towards delivering safer versions of non-reclosable blister-packed drugs. The legislation introduces a child-resistance standard based on the BS8404 test, which requires blister packs to be both child-resistant and senior-friendly, ensuring that the addition of barriers for children do not prevent the elderly from accessing capsules. This new standard has now been introduced for paracetamol, aspirin and iron tablets (containing more than 24mg of iron per tablet).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Jonathan Bobbett, Managing Director at Pill protect™

Jonathan Bobbett is the owner and Managing Director of Pill protectTM, which is part of Three Point Blue Ltd, the holding company for Jonathan's business interests. In addition to Pill protectTM, this includes Bobbett Design, a major branding and design consultancy that has been running for more than 15 years and Blueprint Management Ltd, a specialist print procurement and print management business.

spacer
Jonathan Bobbett
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals

Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >>

White Papers

Achieve full compliance with tamper-verification pharma solutions

UPM Raflatac

UPM Raflatac has developed a range of pharmaceutical labelling products to support compliance with the Falsified Medicines Directive on packaging for prescription drugs and high-risk, over-the-counter medicines. Few solutions offer the same ease of adoption for meeting the February 2019 deadline.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement